Toxic neuropathy in patients with pre-existing neuropathy
- 28 January 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (2) , 337-340
- https://doi.org/10.1212/01.wnl.0000043691.53710.53
Abstract
The authors report significant worsening of a pre-existing neuropathy in six patients who received “non-toxic” dosages of known neurotoxic agents. Before treatment, baseline total neuropathy score (TNS) averaged 9.5 (range 0 to 19). After chemotherapy (Taxol [125 to 175 mg/m2 × 4]; vincristine [2 to 5 mg]; cisplatin [40 mg/m2 × 8]; and thalidomide [60 g]), the TNS averaged 22 (range 13 to 29). The authors conclude that functionally disabling toxic neuropathy can occur in patients with pre-existing neuropathy at standard doses.Keywords
This publication has 8 references indexed in Scilit:
- Thalidomide: current and potential clinical applicationsPublished by Elsevier ,2004
- Chemotherapy-induced peripheral neuropathyZeitschrift für Neurologie, 2002
- Acute deterioration of Charcot-Marie-Tooth disease IA (CMTIA) following 2 mg of vincristine chemotherapyAnnals of Oncology, 2000
- Total neuropathy scoreNeurology, 1999
- Vincristine neuropathy in type I and type II charcot‐marie‐tooth disease (hereditary motor sensory neuropathy)Medical and Pediatric Oncology, 1995
- Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studiesAnnals of Neurology, 1994
- Development of polyneuropathy during thalidomide therapyBritish Journal of Dermatology, 1985
- VINCRISTINE NEUROPATHYBrain, 1973